US EditionCofares Beats Record Sales and Reaches 4,580 Million in 2025
5 Articles
5 Articles
"These results mark an unprecedented milestone and guarantee a responsible, efficient and coherent management," says its president, Eduardo Pastor.
The Cooperative increases its BAI by 19%, and its gross operating result (EBITDA) stands at 49.1 million euros. In 2025 it allocates 45 million euros, which reinforces the cooperative structure to continue offering the best service to its partners. It advances in its financial security policy, raising its coverage rate by 70.7% (according to Banco de España criteria). Eduardo Pastor, president of Cofares: “These results mark an unprecedented mil…
Cofares has closed 2025 with the best results of its history by registering sales of 4,580 million euros, 7.4% more than the previous year, consolidating its leadership in pharmaceutical distribution in Spain, with a quota of close to 30%. The gross operating result (Ebitda) reaches 49.1 million euros (+12%) and the profit before taxes is 18.1 million, 19% higher than the previous year. Eduardo Pastor, president of the cooperative, has emphasize…
Cofares expects sales of €4.58 billion in 2025, representing a 7.4% increase over the previous year. This unprecedented figure further solidifies the Cooperative's position as the leader in the pharmaceutical distribution sector, with a market share of nearly 30%. Furthermore, gross operating profit (EBITDA)—an indicator used to analyze business profitability—grew by 12%, reaching €49.1 million. In a challenging year marked by profound geopoliti…
The pharmaceutical cooperative Cofares has today presented at its national headquarters the forecast and advance of economic results corresponding to the year 2025, in a meeting with media in which it has placed the focus on a new sales record driven by "the diversification and capillarity of the largest distribution network of medicines in the country." This has been highlighted by its president, Eduardo Pastor, who, together with the general d…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
